back to top
HomeTagsSquamous

Squamous

Akeso Printed Ivonescimab plus Ligufalimab as First-Line Remedy for PD-L1-Constructive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 By Investing.com

Head-to-Head Section 3 Trial In comparison with Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ -- On the 2024 European Society for Medical Oncology (ESMO)...

Most Popular

spot_img